Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Overview of attention for article published in Clinical Cancer Research, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 13 X users

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 44 publications that cite this research output.

44

The most recent citing publications are shown below. View all 44 publications that cite this research output on Dimensions.

Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors

Article in Journal of Medicinal Chemistry (August 2024)

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Article in Molecular Cancer (July 2024)

A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors

Article in ESMO Open (July 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.